晶澳科技(002459.SZ)50億元定增結果出爐:廣發基金、財通基金及廣發證券等參投
格隆匯5月11日丨晶澳科技(002459.SZ)發佈非公開發行A股股票之發行情況報吿書暨上市公吿書,確定此次發行價為67.22元/股,發行數量為7438.2624萬股,募集資金總額約50億元。募集資金扣除發行費用後將全部用於年產20GW單晶硅棒和20GW單晶硅片項目、高效太陽能電池研發中試項目和補充流動資金。
最終確定21家機構獲得配售。此次發行最終配售結果如下:

此次非公開發行新增股份7438.2624萬股,此次發行新增股份將於2022年5月16日在深圳證券交易所上市。新增股份上市首日公司股價不除權,股票交易設漲跌幅限制。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.